HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target.

HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target.

Publication date: Aug 07, 2019

Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, and gives rise to metastases in 50% of cases. The presence of an inflammatory phenotype is a well-known risk factor for the development of metastases. This inflammatory phenotype is characterized by the presence of high numbers of lymphocytes and macrophages, and a high expression of the HLA Class I and II antigens. An abnormal expression of HLA Class I may influence cytotoxic T lymphocyte (CTL) as well as Natural Killer (NK) cell responses. We provide a comprehensive review regarding the inflammatory phenotype in UM and the expression of locus- and allele-specific HLA Class I and of Class II antigens in primary UM and its metastases. Furthermore, we describe the known regulators and the role of genetics (especially chromosome 3 and BRCA-Associated Protein 1 (BAP1 status)), and, last but not least, the effect of putative therapeutic treatments on HLA expression.

Souri, Z., Wierenga, A.P.A., Mulder, A., Jochemsen, A.G., and Jager, M.J. HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target. 23709. 2019 Cancers (Basel) (11):8.

Concepts Keywords
Allele Natural killer cell
Antigens Major histocompatibility complex
Basel BAP1
Chromosome Uveal melanoma
Cytotoxic Branches of biology
HLA Melanoma
Locus
Lymphocyte
Lymphocytes
Macrophages
Malignancy
Melanoma
Metastases
Phenotype
Risk Factor
Uveal Melanoma

Semantics

Type Source Name
disease MESH inflammation
gene UNIPROT MAGI1
gene UNIPROT BAP1
gene UNIPROT RNF2
gene UNIPROT TNFRSF10B
disease MESH development
disease MESH risk factor
disease MESH metastases
disease MESH Malignancy
disease DOID Uveal Melanoma
disease MESH Uveal Melanoma

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *